CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)
Article in Heliyon (November 2023)
The most recent citing publications are shown below. View all 100 publications that cite this research output on Dimensions.
Article in Heliyon (November 2023)
Article in Naunyn-Schmiedeberg's Archives of Pharmacology (October 2023)
Article in Frontiers in Immunology (August 2023)